Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,296
  • Shares Outstanding, K 60,094
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -112,670 K
  • 60-Month Beta 1.85
  • Price/Sales 9.84
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade KRON with:

Options Overview Details

View History
  • Implied Volatility 297.25% ( +120.13%)
  • Historical Volatility 54.67%
  • IV Percentile 68%
  • IV Rank 18.66%
  • IV High 1,466.97% on 03/15/24
  • IV Low 28.89% on 07/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 95
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,449
  • Open Int (30-Day) 1,740

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.34
  • Low Estimate -0.55
  • Prior Year -0.46
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +13.33%
on 04/23/24
1.3200 -22.73%
on 04/04/24
-0.2400 (-19.05%)
since 04/03/24
3-Month
0.9000 +13.33%
on 04/23/24
1.4000 -27.14%
on 03/11/24
-0.0600 (-5.56%)
since 02/02/24
52-Week
0.7310 +39.53%
on 11/14/23
2.2900 -55.46%
on 07/13/23
-0.6600 (-39.29%)
since 05/03/23

Most Recent Stories

More News
5 Microcap Stocks With 65% or More Upside Potential

While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.

BTBT : 2.20 (+2.33%)
^BTCUSD : 63,878.85 (+1.61%)
ERJ24 : 3,144.04s (-0.63%)
GOEV : 2.77 (-2.12%)
KRON : 1.0200 (-0.97%)
OGI : 1.8550 (-1.33%)
QBTS : 1.4000 (-3.45%)
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates

Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -6.98% and 89.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

KRON : 1.0200 (-0.97%)
IKNA : 1.3200 (unch)
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

KRON : 1.0200 (-0.97%)
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

KRON : 1.0200 (-0.97%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

KRON : 1.0200 (-0.97%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...

KRON : 1.0200 (-0.97%)
Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 311.9% upside potential for Kronos Bio, Inc. (KRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

KRON : 1.0200 (-0.97%)
Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know

Kronos Bio, Inc. (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KRON : 1.0200 (-0.97%)
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...

KRON : 1.0200 (-0.97%)
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid...

KRON : 1.0200 (-0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 1.1360
2nd Resistance Point 1.0980
1st Resistance Point 1.0590
Last Price 1.0200
1st Support Level 0.9820
2nd Support Level 0.9440
3rd Support Level 0.9050

See More

52-Week High 2.2900
Fibonacci 61.8% 1.6945
Fibonacci 50% 1.5105
Fibonacci 38.2% 1.3265
Last Price 1.0200
52-Week Low 0.7310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar